749 related articles for article (PubMed ID: 25243494)
1. Drugs in Phase II clinical trials for the treatment of age-related macular degeneration.
Tolentino MJ; Dennrick A; John E; Tolentino MS
Expert Opin Investig Drugs; 2015 Feb; 24(2):183-99. PubMed ID: 25243494
[TBL] [Abstract][Full Text] [Related]
2. Prevention and treatment of age-related macular degeneration: an update for pharmacists.
Marshall LL; Roach JM
Consult Pharm; 2013 Nov; 28(11):723-37. PubMed ID: 24217192
[TBL] [Abstract][Full Text] [Related]
3. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration.
Dixon JA; Oliver SC; Olson JL; Mandava N
Expert Opin Investig Drugs; 2009 Oct; 18(10):1573-80. PubMed ID: 19694600
[TBL] [Abstract][Full Text] [Related]
4. Emerging treatments for wet age-related macular degeneration.
Smith AG; Kaiser PK
Expert Opin Emerg Drugs; 2014 Mar; 19(1):157-64. PubMed ID: 24555421
[TBL] [Abstract][Full Text] [Related]
5. Anti-VEGF agents for age-related macular degeneration.
Ozkiris A
Expert Opin Ther Pat; 2010 Jan; 20(1):103-18. PubMed ID: 20021287
[TBL] [Abstract][Full Text] [Related]
6. Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration.
Boltz A; Ruiß M; Jonas JB; Tao Y; Rensch F; Weger M; Garhöfer G; Frantal S; El-Shabrawi Y; Schmetterer L
Ophthalmology; 2012 Aug; 119(8):1615-20. PubMed ID: 22521084
[TBL] [Abstract][Full Text] [Related]
7. [Review and expert opinion in age related macular degeneration. Focus on the pathophysiology, angiogenesis and pharmacological and clinical data].
Weber M; Sennlaub F; Souied E; Cohen SY; Béhar-Cohen F; Milano G; Tadayoni R
J Fr Ophtalmol; 2014 Sep; 37(7):566-79. PubMed ID: 25190312
[TBL] [Abstract][Full Text] [Related]
8. Recent Developments in the Treatment of Wet Age-related Macular Degeneration.
Papadopoulos Z
Curr Med Sci; 2020 Oct; 40(5):851-857. PubMed ID: 32980899
[TBL] [Abstract][Full Text] [Related]
9. Anti vascular endothelial growth factor sequential therapy for neovascular age-related macular degeneration: is this the new deal?
Neri P; Mariotti C; Arapi I; Bambini E; Giovannini A
Curr Med Res Opin; 2012 Mar; 28(3):395-400. PubMed ID: 22283373
[TBL] [Abstract][Full Text] [Related]
10. Ranibizumab for age-related macular degeneration.
Dhoot DS; Kaiser PK
Expert Opin Biol Ther; 2012 Mar; 12(3):371-81. PubMed ID: 22309606
[TBL] [Abstract][Full Text] [Related]
11. Advances in pharmacotherapy for wet age-related macular degeneration.
Santarelli M; Diplotti L; Samassa F; Veritti D; Kuppermann BD; Lanzetta P
Expert Opin Pharmacother; 2015; 16(12):1769-81. PubMed ID: 26165696
[TBL] [Abstract][Full Text] [Related]
12. Poor responders to bevacizumab pharmacotherapy in age-related macular degeneration and in diabetic macular edema demonstrate increased risk for obstructive sleep apnea.
Nesmith BL; Ihnen M; Schaal S
Retina; 2014 Dec; 34(12):2423-30. PubMed ID: 25062438
[TBL] [Abstract][Full Text] [Related]
13. Aflibercept for age-related macular degeneration: a game-changer or quiet addition?
Browning DJ; Kaiser PK; Rosenfeld PJ; Stewart MW
Am J Ophthalmol; 2012 Aug; 154(2):222-6. PubMed ID: 22813448
[TBL] [Abstract][Full Text] [Related]
14. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C
Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.
Peden MC; Suñer IJ; Hammer ME; Grizzard WS
Ophthalmology; 2015 Apr; 122(4):803-8. PubMed ID: 25596618
[TBL] [Abstract][Full Text] [Related]
16. Investigational drugs in clinical trials for macular degeneration.
Tolentino MJ; Tolentino AJ
Expert Opin Investig Drugs; 2022 Oct; 31(10):1067-1085. PubMed ID: 35962560
[TBL] [Abstract][Full Text] [Related]
17. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview.
Semeraro F; Morescalchi F; Duse S; Gambicorti E; Romano MR; Costagliola C
Expert Opin Drug Saf; 2014 Jun; 13(6):785-802. PubMed ID: 24809388
[TBL] [Abstract][Full Text] [Related]
18. Development of gene therapy for treatment of age-related macular degeneration.
Askou AL
Acta Ophthalmol; 2014 Jul; 92 Thesis3():1-38. PubMed ID: 24953666
[TBL] [Abstract][Full Text] [Related]
19. [Monoclonal antibodies targeting VEGF in ophthalmology: the case of exudative age-related macular degeneration].
Leveziel N; Soubrane G; Souied EH
Med Sci (Paris); 2009 Dec; 25(12):1105-7. PubMed ID: 20035686
[TBL] [Abstract][Full Text] [Related]
20. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
Ferrara N; Damico L; Shams N; Lowman H; Kim R
Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
